Haben selektive COX-2-Hemmer unerwünschte renale und kardiovaskuläre Wirkungen [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].

Détails

ID Serval
serval:BIB_5BF09D2EFD14
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Haben selektive COX-2-Hemmer unerwünschte renale und kardiovaskuläre Wirkungen [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].
Périodique
Praxis
Auteur(s)
Mathieu C., Meier P., Meyer zu Starten A., Burnier M.
ISSN
1661-8157 (Print)
ISSN-L
1661-8157
Statut éditorial
Publié
Date de publication
2005
Volume
94
Numéro
47
Pages
1851-1858
Langue
allemand
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Selective cyclooxygenase-2-inhibitors (COX-2) were developed as an alternative to the non-steroidal anti-inflammatory drugs (NSAID) in order to reduce their known gastrointestinal and renal toxicity. Several recent studies have shown the complex mechanism of the cyclooxygenase-2. The inhibition of the COX-2 has effects on renal hemodynamics, renal salt and water retention and may increase the thromboembolic and therefore the cardiovascular risk. The renal toxicity of the COX-2 inhibitors is similar to that of traditional NSAID. Regarding these data, COX-2 inhibitors should be prescribed with much caution to high risk patients, that is, patients with renal failure and/or cardiovascular diseases.
Mots-clé
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Anti-Inflammatory Agents, Non-Steroidal/toxicity, Cardiovascular Diseases/chemically induced, Cardiovascular Diseases/mortality, Cyclooxygenase 2 Inhibitors/administration & dosage, Cyclooxygenase 2 Inhibitors/toxicity, Dose-Response Relationship, Drug, Humans, Kidney Diseases/chemically induced, Kidney Diseases/mortality, Naproxen/administration & dosage, Naproxen/toxicity, Pyrazoles/administration & dosage, Pyrazoles/toxicity, Risk Assessment, Sulfonamides/administration & dosage, Sulfonamides/toxicity, Thromboembolism/chemically induced, Thromboembolism/mortality
Pubmed
Création de la notice
06/09/2011 10:44
Dernière modification de la notice
20/08/2019 14:14
Données d'usage